UK markets closed

Valbiotis SA (ALVAL.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
6.36-0.06 (-0.93%)
At close: 05:35PM CET

Valbiotis SA

rue Paul Vatine
12th Floor
Périgny 17180
France
33 5 46 28 62 58
https://www.valbiotis.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees35

Key executives

NameTitlePayExercisedYear born
Mr. Sébastien PeltierCo-Founder, Chairman & CEON/AN/A1978
Mr. Jocelyn PineauCo-Founder, CFO & DirectorN/AN/AN/A
Mr. Sebastien BessyChief Operating Marketing & Bus. Officer and DirectorN/AN/AN/A
Mr. Pascal Sirvent Ph.D.CSO & DirectorN/AN/AN/A
Ms. Murielle CazaubielCMO & DirectorN/AN/AN/A
Dr. Josep InfestaHead of Global Bus. Devel.N/AN/AN/A
Ms. Agnès TixierExec. Director of Credit Mutuel & Equity SCR and Member of Supervisory BoardN/AN/A1969
Mr. Philippe SibourChief Exec. Officer of Alliance ConsultingN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Valbiotis SA engages in the research and development of health nutrition products to prevent metabolic diseases in response to unmet medical needs. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070 for hypercholesterolemia; TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease; and TOTUM-854 for arterial hypertension. It has a strategic partnership with Nestlé Health Science. The company was founded in 2014 and is headquartered in Périgny, France.

Corporate governance

Valbiotis SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.